Prognostic and Predictive Role of HER2 Expression in Metastatic Gastric Cancer in Turkish Patients
Cancer Research Journal
Volume 1, Issue 2, July 2013, Pages: 20-25
Received: Jun. 20, 2013; Published: Aug. 10, 2013
Views 3442      Downloads 169
Mustafa Yıldırım, Ministry of Health Batman Regional Government Hospital, Department of Medical Oncology, Batman, Turkey
Arsenal Sezgin, Antalya Education and Research Hospital, Department of Pathology, Antalya, Turkey
Utku Dönem Dilli, Antalya Education and Research Hospital, Department of Medical Oncology, Antalya, Turkey
Dinc Süren, Antalya Education and Research Hospital, Department of Pathology, Antalya, Turkey
Mustafa Yıldız, Antalya Education and Research Hospital, Department of Medical Oncology, Antalya, Turkey
Vildan Kaya, Süleyman Demirel University School of Medicine, Department of Radiation Oncology, Isparta, Turkey
Cem Sezer, Antalya Education and Research Hospital, Department of Pathology, Antalya, Turkey
Nurullah Bülbüller, Antalya Education and Research Hospital, Department of General Surgery, Antalya, Turkey
Article Tools
Follow on us
Background: In this study, we investigate the role of HER2 expression in prediction of the response to treatment combination including dosetaxel, cisplatin and 5-FU which is used in metastatic gastric cancer in Turkish patients. Methods: Patients who were histopathologically diagnosed with metastatic gastric cancer at the Antalya Training and Research Hospital, Clinic of Medical Oncology from 2008 to 2010 were included in this study. Results: IHC assessment identified 4 patients (25%) 0 / negative, 5 patients (31.3%) 1+ / negative, 4 patients (25%) 2 + / suspected, and 3 patients (18.8%) 3 + / positive. The relationship between HER2 expression and the response using chi-square test was not statistically significant. Conclusions: We believe that identification of patients who will respond to chemoterapy combination is important to prevent complications. The important shortcomings in our study include covering a small number of patients and the use of FISH method. Therefore, we believe that further studies using FISH method with more patients are required to investigate the role of HER2 expression in predicting the response to DCF chemotherapy combination.
Gastric cancer, Prognosis, HER 2, Chemotherapy, Docetaxel, Cisplatin
To cite this article
Mustafa Yıldırım, Arsenal Sezgin, Utku Dönem Dilli, Dinc Süren, Mustafa Yıldız, Vildan Kaya, Cem Sezer, Nurullah Bülbüller, Prognostic and Predictive Role of HER2 Expression in Metastatic Gastric Cancer in Turkish Patients, Cancer Research Journal. Vol. 1, No. 2, 2013, pp. 20-25. doi: 10.11648/j.crj.20130102.12
Koeppen HK, Wright BD, Burt AD, Quirke P, McNicol AM, Dybdal NO, Sliwkowski MX, Hillan KJ. Overexpression of HER2⁄neu in solid tumours: an immunohistochemical survey. Histopathology. 2001; 38: 96–104.
Pappas A, Lagoudianakis E, Seretis C, Tsiambas E, Koronakis N, Toutouzas K, Katergiannakis V, Manouras A. Clinical role of HER-2/neu expression in colorectal cancer. J BUON. 2013; 18: 98-104.
Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ. Quantitative association between HER-2 ⁄ neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 2003; 95: 142–53.
Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin. Breast Cancer. 2004; 5: 63–9.
Yonemura Y, Ninomiya I, Ohoyama S, Kimura H, Yamaguchi A, Fushida S, Kosaka T, Miwa K, Miyazaki I, Endou Y. Expression of c-erbB-2 protein is an independent indicator of poor short-term prognosis in patients with gastric carcinoma. Cancer. 1991; 67: 2914-8.
Bayrak M, Olmez OF, Kurt E, Cubukcu E, Evrensel T, Kanat O, Manavoglu O. Prognostic significance of c-erbB2 overexpression in patients with metastatic gastric cancer. Clin Transl Oncol. 2013; 15: 307-12.
Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Yoo CH, Son BH, Cho EY, Chae SW, Kim EJ, Sohn JH, Ryu SH, Sepulveda AR. HER2-neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci. 2006; 51: 1371-9.
Glimelius B, Ekström K, Hoffman K, Graf W, Sjödén PO, Haglund U, Svensson C, Enander LK, Linné T, Sellström H, Heuman R. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997; 8: 163–8.
Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA; V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006; 24: 4991–7.
Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008; 52: 797-805.
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74-108.
Yano T, Doi T, Ohtsu A, Boku N, Hashizume K, Nakanishi M, Ochiai A. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep. 2006; 15: 65-71.
Tanner M, Hollmén M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K, Isola J. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005; 16: 273-8.
Uchino S, Tsuda H, Maruyama K, Kinoshita T, Sasako M, Saito T, Kobayashi M, Hirohashi S. Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. Cancer. 1993; 72: 3179-84.
Mizutani T, Onda M, Tokunaga A, Yamanaka N, Sugisaki Y. Relationship of c-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer. 1993; 72: 2083-8.
Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, Matsuda M, Sakaguchi T, Hirao T, Nakano H. The prognostic significance of amplification and overexpression of c-met and c-erbB-2 in human gastric carcinomas. Cancer. 1999; 85: 1894-902.
Im SA, Lee KE, Nam E, Kim DY, Lee JH, Han HS, Seoh JY, Park HY, Cho MS, Han WS, Lee SN. Potential prognostic significance of p185(HER2) overexpression with loss of PTEN expression in gastric carcinomas. Tumori. 2005; 91: 513-21.
Boone JJ, Bhosle J, Tilby MJ, Hartley JA, Hochhauser D. Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents. Mol Cancer Ther. 2009; 8: 3015-23.
Pietrantonio F, De Braud F, Da Prat V, Perrone F, Pierotti MA, Gariboldi M, Fanetti G, Biondani P, Pellegrinelli A, Bossi I, Di Bartolomeo M. A review on biomarkers for prediction of treatment outcome in gastric cancer. Anticancer Res. 2013; 33: 1257-66.
Wang L, Wei J, Qian X, Yin H, Zhao Y, Yu L, Wang T, Liu B. ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer. 2008; 8: 97.
Gunturu KS, Woo Y, Beaubier N, Remotti HE, Saif MW. Gastric cancer and trastuzumab: first biologic therapy in gastric cancer. Ther Adv Med Oncol. 2013; 5: 143-51.
Yildirim M, Suren D, Goktas S, Dilli UD, Kaya C, Copuroglu R, Yildiz M, Sezer C. The predictive role of Bcl-2 expression in operable locally advanced or metastatic gastric carcinoma. J BUON. 2012; 17: 106-9.
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
Tel: (001)347-983-5186